Wednesday, October 24, 2012

Fujifilm Kyowa Kirin Biologics to initiate development of biosimilar of bevacizumab (Avastin)

FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.  a 50:50 joint venture between FUJIFILM Corporation and Kyowa Hakko Kirin Co., Ltd. has announced that they would initiate development of a biosimilar version of bevacizumab (Avastin). Avastin exclusivity in the US expires in 2019. Current annual sales of Avastin in close to $6.5 billion and is still growing driven by indication exapansion. It remains uncertain, whether Avastin would sustain its sales until exclusivity, as we are seeing heightened competition in oncology. There are certain NCE's  under development which have shown early promise of better clincial profile than Avastin in certain indications.


Presently Fujifilm kyowa kirin biologics Ltd. is developing a biosimilar of the fully human anti-TNF-α monoclonal antibody, adalimumab, a drug with dramatic therapeutic effects for rheumatoid arthritis, and is proceeding with preparations to begin clinical trials in Europe in the first half of 2013. Fujifilm Kyowa Kirin Biologics intends to develop the biosimilar version of bevacizumab as the second drug in their lineup. After introducing the production cell line already produced by Kyowa Hakko Kirin, Fujifilm Kyowa Kirin Biologics plans to start clinical trials in 2014.


Enter your email address:


Delivered by FeedBurner